Gilead Sciences said it is planning a phase 2/3 clinical trial of remdesivir for the treatment of pediatric COVID-19 patients.

The study will evaluate the safety and efficacy of the antiviral in approximately 50 pediatric patients with moderate to severe COVID-19, including newborns through adolescents. The trial will be conducted at more than 30 sites in the U.S. and Europe.

Gilead has been providing remdesivir to pediatric patients with severe COVID-19 under compassionate use since February, and under an Emergency Use Authorization granted by the FDA last month.